Company Name, Ticker, Customers, else..

Turnstone Biologics Corp (NASDAQ: TSBX)

Sector • Healthcare Industry • Biotechnology & Pharmaceuticals

Industry • Biotechnology & Pharmaceuticals

Sector • Healthcare

Turnstone Biologics 's

Name: Turnstone Biologics Corp Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TSBX Sales vs. its Competitors Q2 2025

Comparing the current results to its competitors, Turnstone Biologics reported Revenue decrease in the 2 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 1.33 %, recorded in the same quarter.

• List of TSBX Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Turnstone Biologics Corp , slower than the average decrease reported by the company's competitors of -3.44 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -3.44 %

<< TSBX Stock Performance Comparisons

<< See the full list of TSBX competitors

*Market share is calculated based on total revenue.

TSBX's Stock Performance relative to its Competitors

Publicly Traded Peers of Turnstone Biologics Corp

Instil Bio Inc
Share Performance

-34.16%

This Year

Instil Bio Inc

Profile

Instil Bio Inc operates with a business model focusing on developing and commercializing innovative cell therapy products for the treatment of cancer. They aim to leverage advanced technologies and strategic partnerships to advance their pipeline and bring novel therapies to market.

More about Instil Bio Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 50.322 mill.	$ 8.968 mill.	$ -30.281 mill.

Exelixis Inc
Share Performance

+29.07%

This Year

Exelixis Inc

Profile

Exelixis Inc's business model is focused on the discovery, development, and commercialization of innovative therapies for the treatment of cancer.

More about Exelixis Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 14,606.719 mill.	$ 2,435.920 mill.	$ 1,896.089 mill.

Tradeup Acquisition Corp
Share Performance

-32.46%

One Year

Tradeup Acquisition Corp

Profile

Estrella Immunopharma Inc is a biotechnology company that focuses on developing innovative immunotherapies. They have a business model centered around researching, developing, and commercializing novel treatments for various diseases. Their approach includes leveraging the power of the immune system to target and eradicate diseases, with a particular emphasis on cancer.

More about Tradeup Acquisition Corp's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 30.494 mill.	$ - mill.	$ -17.378 mill.

Cardiol Therapeutics inc
Share Performance

-6.94%

Over The Past 5 Days

Cardiol Therapeutics inc

Profile

Cardiol Therapeutics Inc. operates on a business model focused on the research and development of pharmaceutical-grade cannabidiol (CBD) and targeted therapies for cardiovascular diseases. The company aims to leverage its expertise to develop innovative and effective treatments to address unmet medical needs in the field of heart-related conditions.

More about Cardiol Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 174.849 mill.	$ - mill.	$ -25.905 mill.

Compass Therapeutics Inc
Share Performance

-13.29%

30 Days

Compass Therapeutics Inc

Profile

Compass Therapeutics Inc operates as a biotechnology company focused on discovering and developing novel antibody therapeutics for the treatment of cancer and autoimmune diseases. Their business model revolves around leveraging their proprietary Targeted Immunomodulation platform to identify and advance multiple antibody candidates through preclinical and clinical development stages.

More about Compass Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 383.870 mill.	$ - mill.	$ -73.446 mill.

50 more competitors available

Sources: Turnstone Biologics Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Monday, September 14, 2026 4:00 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Turnstone Biologics Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.